PF-06747143 induces malignant cell death by Fc-effector function activity. ADCC activity was evaluated by incubating 100 nM PF-06747143, m15-IgG1, m15-IgG4, rituximab, or respective negative control Ab’s for 4 hours in the presence of NK92 158V effector killer cells (effector:target cell ratio 10:1) with tumor target cells: Ramos (A) and MV4-11 and OPM-2 (B). Cell lysis was measured by ToxiLight bioluminescent cytotoxicity assay. Experiments were performed in quadruplicates. Bars represent SEM. CDC was assessed by incubating Daudi NHL target cells in the presence of 2.5% human complement for 4 hours. Experiments were performed in duplicates. Bars represent standard deviations. (C) Cells were treated with 33 nM of IgG1 control Ab, m15-IgG1, m15-IgG4, or rituximab. (D) Cells were treated with 33 nM of IgG1 control Ab, m15-IgG1, PF-06747143, or rituximab.